Business & Finance Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
By
· September 21, 2026 · 1 min read
This article was originally published by
MarketWatch
and is republished here under license.
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
Related
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore…
By
· September 21, 2026 · 1 min read
Jerry Rizzieri, Mizuho Securities USA president and CEO, says we're in a healthy environment for dealmaking. He also speaks about…
By
· September 21, 2026 · 1 min read
Trump's media ban on three news outlets could limit the public's visibility into the president's actions.…
By
· September 21, 2026 · 1 min read
Leave a Reply